TechAILatest.newsTrackers

Isomorphic Labs news

AI drug discovery company1 story

Isomorphic Labs is a London-based AI drug discovery company spun out of DeepMind under Alphabet in 2021 and led by Demis Hassabis.

Every story about Isomorphic Labs

Abstract illustration of rising bars and a growth lineTech AI Latest

Isomorphic Labs raises $5 billion Series C, then signs an oncology deal with MSD

AI Business & Funding

Isomorphic Labs raised $5 billion on 17 November 2026 in a round co-led by Greenoaks and Sequoia, then signed a cancer drug research deal with MSD.

Summary

Isomorphic Labs, the Alphabet drug discovery company led by Demis Hassabis, announced a $5 billion Series C on 17 November 2026, co-led by Greenoaks and Sequoia Capital with Andreessen Horowitz joining. It did not disclose a valuation. Two days later Merck, known as MSD outside the US and Canada, signed a research collaboration with the company on a cancer target. Isomorphic has not yet put a drug into human trials.